Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
about
Rasagiline for levodopa-induced motor complications in ParkinsonĀ“s diseasePiribedil for levodopa-induced complications in Parkinson's diseasePiribedil versus levodopa in early Parkinson's diseaseDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Dopamine agonists in Parkinson's diseaseNeuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugsReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.New small molecules for the treatment of Parkinson's disease.Pharmacotherapy in Parkinson's disease: case studies.Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine AgonistSeniors with Parkinson's disease: initial medical treatment.Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort studyAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.How to optimize the treatment of early stage Parkinson's disease.Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexoleRole and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease.Clinical aspects and management of levodopa-induced dyskinesia.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Role of dopamine agonists in Parkinson's disease: an update.Protection against Parkinson's disease progression: clinical experience.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.Milestones in Parkinson's disease therapeutics.Pramipexole extended release in Parkinson's disease.Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.The impact of subthalamic deep brain stimulation on nigral neuroprotection-myth or reality?The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Treatment in early Parkinson's disease: the Norwegian ParkWest study.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.Novel levodopa formulations in the treatment of Parkinson's disease.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
P2860
Q24243502-A858B81A-F207-46BD-93FA-5C78FA784EA7Q24244549-D42EDF64-E0CF-48B4-8F53-4BD0051178EAQ24244961-4E1B0278-0794-4DA3-8FC8-E4A4EDF2FFB0Q27021464-C01BBECB-818B-4E0B-8DF6-F3E34FF53D4FQ28276692-1626678D-A121-46C9-8FD0-05F949E6EA91Q28534024-577A9830-DEF1-4628-8779-B77D624943BBQ33260250-282F9AB9-1E41-40D0-8CC1-C21519C39FBCQ33465315-BCD3A265-8C52-4FB0-8A07-F23F79F4B169Q33604937-E0B0FA0C-45AA-40D5-BC26-3310E8FEDB21Q33636631-B3F0BA6F-75A8-48AB-90D5-5C0DE28F4A70Q34409459-0A985E4F-D468-4E6B-AA72-E7F6B846B235Q34504316-1A7BBBEE-A984-499E-BEB9-8D644FD3234CQ34508143-A088A4A9-756B-4BFD-A907-A117069757A8Q35016008-F4DAA325-85C4-42D8-8FC1-F6E6CB443FDEQ35589979-4A8792F8-C16F-450A-8871-BF7E6F2F0864Q35599297-7B48AFD0-3DED-41AB-980D-1428256DB09DQ35654026-759CBDDE-6A6B-4682-9701-F46BEB51FA24Q35716858-46ABF3A6-5CDD-4278-8A7A-E3DBE206C261Q35885133-0DF168A6-370F-41CD-AE3D-5EF745DDF4F1Q36022700-B6A93951-F2D7-45C7-9D92-B578D77F8619Q36573882-34F83F71-5C51-4962-98F9-D67E7CF8B7DBQ36972701-A8309B46-763F-4CC6-9353-372ABC99AF5DQ37131239-96C6F207-56BA-4A01-BDA6-BDC509383E48Q37736512-5070BE21-2D07-409D-A6DA-77B44D85A10FQ37776519-DE8F2254-10B4-4576-ADD2-B412D5FEF662Q37790274-603B7A5B-F30F-41F7-91BA-3B9FFC4207C7Q37831397-8458F404-B148-4938-A16C-A77DE33267E4Q37882596-ECA03A13-FC79-4DF1-9256-A87762650F88Q37921759-71252325-93EE-4C41-B3D2-5C8FEB29F349Q37924626-B2650DB5-06F5-4A31-9014-D018BC1E6CF9Q37944953-A1D67193-1D7A-4BDE-854C-BE818E1E968CQ37948713-AB8CCAA4-FA72-429C-8F49-371860539435Q37973462-88D7B5CC-7888-4590-A403-32B515DE26CCQ37979869-92921DE0-226E-4792-A4A7-231FDC4BF794Q38063341-D30F0193-13D1-45D4-9A63-60DC2C0C57CAQ38070888-377DEF18-EBE3-4E4A-A396-42620359EE14Q38112217-FD597345-423C-47C8-AF01-29A34B2CDC47Q38178754-899FF809-D82C-48A1-A999-218989E6565CQ38314257-65D55ABD-F200-4656-8E24-1FBF998BA2B9Q38485023-30827722-87B5-4991-8EE7-CA92FF2A6428
P2860
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006幓ć®č«ę
@ja
2006幓å¦ęÆęē«
@wuu
2006幓å¦ęÆęē«
@zh-cn
2006幓å¦ęÆęē«
@zh-hans
2006幓å¦ęÆęē«
@zh-my
2006幓å¦ęÆęē«
@zh-sg
2006幓åøč”ęē«
@yue
2006幓åøč”ęē«
@zh
2006幓åøč”ęē«
@zh-hant
name
Pergolide versus levodopa mono ...... patients: The PELMOPET study.
@en
Pergolide versus levodopa mono ...... patients: The PELMOPET study.
@nl
type
label
Pergolide versus levodopa mono ...... patients: The PELMOPET study.
@en
Pergolide versus levodopa mono ...... patients: The PELMOPET study.
@nl
prefLabel
Pergolide versus levodopa mono ...... patients: The PELMOPET study.
@en
Pergolide versus levodopa mono ...... patients: The PELMOPET study.
@nl
P2093
P921
P356
P1433
P1476
Pergolide versus levodopa mono ...... patients: The PELMOPET study.
@en
P2093
Alberto LledĆ³
Andrew Wood
Bruno Bergamasco
Donald G Grosset
Erik Wolters
Guy Arnold
Hans-Peter Hundemer
Johannes Schwarz
Klaus L Leenders
Max Dujardin
P304
P356
10.1002/MDS.20724
P407
P577
2006-03-01T00:00:00Z